Epsilogen Ltd.. (9/9/24). "Press Release: Epsilogen Completes £12.5 Million Series B Financing Expansion". London.

	Organisation	Epsilogen Ltd.
	Organisation 2	Novartis Venture Fund (NVF)
	Group	Novartis (Group)
	Product	IgE antibody
	Product 2	venture capital
	Index term	Epsilogen–SEVERAL: investment, 202409 financing round Series B expansion £12.5m from existing investors bringing total round to £43.25m
	Index term 2	Epsilogen–SEVERAL: investment, 202203 financing round Series B £30.75m led by new investor Novartis Venture Fund
	Person	Wilson, Tim (Igem Therapeutics 201804 CEO)
	Person 2	Conway, Simon (FTI Consulting 201412)

> Expansion brings total Series B funds raised to £43.25 million

> Proceeds to support the delivery of clinical Proof of Concept for MOv18 IgE

Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, today announces the completion of a £12.5 million Series B expansion financing bringing the Series B total to £43.25 million. This financing will fund the delivery of clinical Proof of Concept for lead asset MOv18 IgE in a phase Ib trial featuring platinum-resistant ovarian cancer (PROC) as well as further development of the company’s IgE-based pipeline. The financing was entirely conducted by existing investors including British Patient Capital, Novartis Venture Fund, Epidarex Capital, 3B Future Health Fund and ALSA Ventures.

MOv18 IgE is the first therapeutic IgE antibody to enter the clinic. This first-in-class antibody targets folate receptor alpha (FR?), an antigen present on a variety of cancers including ovarian, endometrial, lung and triple negative breast cancer. In a phase I trial, MOv18 IgE was found to be safe and well tolerated with initial signs of clinical activity also seen, as reported in Nature Communications (https://www.nature.com/articles/s41467-023-39679-9). The phase Ib trial is a two-part, dose escalation and expansion trial in patients with FR?-positive PROC whose disease has progressed after =4 prior regimens of anti-cancer therapy.

MOv18 IgE has a unique mechanism of action differentiating it from other agents currently in the clinic and on the market. Key aspects of this mechanism include high affinity binding to its main cognate receptor, FceR1, thereby enabling immunosurveillance and potent myeloid cell driven tumour cell killing. Additionally, IgE antibodies drive modulation of the tumour immune microenvironment to become more pro-inflammatory, leading to increased intra-tumoural levels of activated T cells and tumour killing macrophages.

Tim Wilson, CEO of Epsilogen said “We are delighted to have received strong continued support from our existing investors and we thank them. The promise of IgE to treat cancer is based upon its unique mechanism of action and MOv18 IgE is the first ever to be tested in man. Everything is ready for phase Ib initiation which will occur shortly and we look forward to reporting progress from the trial.”

ENDS

About Epsilogen Ltd

Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE’s natural function is to provide immunological defence against certain parasites. This functionality makes it an ideal treatment of solid tumours due to its strong potency, enhanced tumour access and long tissue half-life.

Epsilogen’s lead product candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic and encouraging data from a completed Phase I trial demonstrated MOv18 IgE to be safe and well tolerated with early signs of clinical activity. Epsilogen has recently successfully completed large scale GMP manufacture of MOv18 IgE (the first time this has been achieved for an IgE antibody) and will initiate a Phase Ib trial in platinum-resistant ovarian cancer patients later this year. The company is also developing a pipeline of IgE therapies in oncology as well as proprietary platforms including IgE bispecifics and unique IgE/IgG combination antibody molecules (IgEGs) with enhanced functionality.

Epsilogen began operations in 2017 as a spin-out of King’s College London and has attracted venture capital financing from Epidarex Capital, Novartis Venture Fund, 3B Future Health, British Patient Capital, ALSA Ventures and Schroders Capital amongst others. Find out more at epsilogen.com.

For more information please contact:

Communications advisor to Epsilogen Ltd:

Simon Conway
Senior Managing Director
FTI Consulting
epsilogen@fticonsulting.com
+44 (0)20 3727 1000

Record changed: 2024-09-12